AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News

$62.31
-1.62 (-2.53 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$61.79
Now: $62.31
$64.85
50-Day Range
$41.29
MA: $54.94
$69.94
52-Week Range
$32.30
Now: $62.31
$74.00
Volume565,082 shs
Average Volume1.02 million shs
Market Capitalization$3.80 billion
P/E Ratio83.08
Dividend YieldN/A
Beta2.26
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Read More
Crispr Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRSP
CUSIPN/A
Phone41-41-561-3277

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$289.59 million
Cash Flow$1.22 per share
Book Value$14.52 per share

Profitability

Net Income$66.86 million

Miscellaneous

Employees188
Market Cap$3.80 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

How has Crispr Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRSP shares have increased by 44.0% and is now trading at $62.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Crispr Therapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics.

When is Crispr Therapeutics' next earnings date?

Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Crispr Therapeutics.

How were Crispr Therapeutics' earnings last quarter?

Crispr Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Tuesday, April, 28th. The company reported ($1.15) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.10. The company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $3.04 million. Crispr Therapeutics had a return on equity of 6.54% and a net margin of 15.73%. The firm's revenue was down 52.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.93) EPS. View Crispr Therapeutics' earnings history.

What price target have analysts set for CRSP?

15 Wall Street analysts have issued 12-month price targets for Crispr Therapeutics' shares. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' stock price to reach $74.42 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View analysts' price targets for Crispr Therapeutics.

Has Crispr Therapeutics been receiving favorable news coverage?

News stories about CRSP stock have been trending extremely positive on Thursday, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Crispr Therapeutics earned a coverage optimism score of 4.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View the latest news aboutCrispr Therapeutics.

Are investors shorting Crispr Therapeutics?

Crispr Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,020,000 shares, an increase of 11.7% from the April 30th total of 3,600,000 shares. Based on an average trading volume of 1,000,000 shares, the short-interest ratio is presently 4.0 days. Approximately 8.5% of the company's stock are short sold. View Crispr Therapeutics' Current Options Chain.

Who are some of Crispr Therapeutics' key competitors?

What other stocks do shareholders of Crispr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Square (SQ), Vertex Pharmaceuticals (VRTX) and Intel (INTC).

Who are Crispr Therapeutics' key executives?

Crispr Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)
  • Dr. Samarth Kulkarni, CEO & Director (Age 40)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)
  • Dr. Tony W. Ho, Head of R&D and Exec. VP
  • Dr. N. Anthony Coles Jr., Sr. Advisor (Age 59)

When did Crispr Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is Crispr Therapeutics' stock symbol?

Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are Crispr Therapeutics' major shareholders?

Crispr Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Nikko Asset Management Americas Inc. (6.17%), Federated Hermes Inc. (1.77%), Morgan Stanley (1.40%), Morgan Stanley (1.40%), Wellington Management Group LLP (1.16%) and Cormorant Asset Management LP (1.03%). Company insiders that own Crispr Therapeutics stock include Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Vertex Pharmaceuticals (Europe. View institutional ownership trends for Crispr Therapeutics.

Which institutional investors are selling Crispr Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Two Sigma Investments LP, Orbimed Advisors LLC, Federated Hermes Inc., Deutsche Bank AG, Two Sigma Advisers LP, JPMorgan Chase & Co., and Squarepoint Ops LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, and Samarth Kulkarni. View insider buying and selling activity for Crispr Therapeutics.

Which institutional investors are buying Crispr Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Morgan Stanley, Morgan Stanley, TimesSquare Capital Management LLC, Casdin Capital LLC, Capital International Investors, Bank of New York Mellon Corp, and Acadian Asset Management LLC. View insider buying and selling activity for Crispr Therapeutics.

How do I buy shares of Crispr Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crispr Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $62.31.

How big of a company is Crispr Therapeutics?

Crispr Therapeutics has a market capitalization of $3.80 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe.

What is Crispr Therapeutics' official website?

The official website for Crispr Therapeutics is www.crisprtx.com.

How can I contact Crispr Therapeutics?

Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.